A new preprint study suggests that Moderna’s COVID-19 vaccine may be significantly more effective against symptomatic disease from the delta variant compared to Pfizer-BioNTech’s vaccine, while the ...

Moderna says its vaccine is 93% effective against symptomatic illness at six months (though this data collection ended before delta emerged in the U.S.). Moderna said its booster candidates also ...

Moderna on Tuesday released preliminary data indicating its vaccine is likely to hold up against several variants of concern, including the Delta variant, which is predicted to become the dominant ...

Preliminary analysis showed the 2025-2026 formula of mNEXSPIKE generated greater than a 16-fold increase in LP.8.1-neutralizing antibodies across age groups Both of Moderna's COVID-19 vaccines for the ...

Moderna said its COVID-19 vaccine demonstrated 93 percent efficacy, with efficacy remaining durable through six months after the second dose’s administration. The announcement was based on a new ...

The study is based on a random sample that included people with asymptomatic infections. Vaccines protect well against severe disease.

If COVID-19 booster shots become an annual precaution, the same way we get a flu shot every year, the next one may be formulated differently. Moderna and Pfizer working on a bivalent vaccine that ...

The Centers for Disease Control and Prevention listed the COVID-19 delta variant as one of its "variants of concern" (VOCs) on June 15. According to the CDC, VOCs can be more contagious, more ...

"We really do believe the virus is here to stay for the long term," a top Moderna executive said.

Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in LP.8.1-neutralizing antibodies across age groups Clinical findings reinforce preclinical data ...